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ABSTRACT 
In patients with chronic kidney disease, treatment with erythropoiesis-stimulating agents (ESA) 
effectively corrects anemia. Most of these patients also need supplementation with regular iron 
injections to secure iron availability for proper erythropoiesis. Following intravenous iron injection, 
non-transferrin bound iron (NTBI) can appear in the circulation, capable of inducing harmful 
oxidative reactions. Direct measurement of free iron with the robust technique electron spin resonance 
(ESR) has not been used to investigate this issue in humans.  
The main purposes of this thesis were to use ESR to study the levels of NTBI and oxidative stress 
after intravenous (IV) iron injection and to compare two commercially available IV iron formulations, 
low-molecular weight iron-dextran (ID) and iron-sucrose (IS), regarding this topic. In addition, the 
impact of two different hemodialysis modalities on iron homeostasis and the effect of modifying the 
ESA administration praxis on ESA requirement, were studied. 
Sixty-four patients on chronic hemodialysis treatment participated in these studies. To investigate 
the appearance of NTBI and induction of oxidative stress, blood samples were collected before and 
after IV iron injections. To compare two different hemodialysis modalities, a prospective, 
randomized, patient-blinded study, with conventional hemodialysis (HD) and on-line 
hemodiafiltration (HDF), in a 2x2 months design, was conducted. Finally, a retrospective register 
study was performed on 18 patients, comparing periods with two different erythropoietin 
administration routines. After injection of IS, a parallel increase in oxidative stress and NTBI was 
noted, while no induction of oxidative stress was seen following injection of ID. After treatment with 
HDF, the levels of the iron-regulating peptide, 25-hepcidin, were in all cases within the reference 
interval. A change in ESA administration regimen, to less frequent dose-adjustments and no withheld 
doses, could be an explanation for the observed approximately 20 % reduction in ESA requirement. 
In conclusion, IS injection, but not ID injection, “leaks” catalytically active iron into the blood 
stream, which then initiates a burst of intravascular oxidative reactions. The increased clearance of 25-
hepcidin by HDF could be of benefit for the dialysis patient, bringing the pathological iron 
homeostasis found in this population toward a more normal state. An erythropoietin regimen with 
optimal frequency of dose adjustments can reduce ESA demand and thereby decrease health care cost.  
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ABBREVIATIONS 
 
! Change 
! Increase 
" Decrease 
AFR ascorbyl free radical 
AU arbitrary units 
BDC-LDL baseline diene conjugation in LDL 
CKD chronic kidney disease 
DFO desferrioxamine 
EPO erythropoietin 
ESA erythropoiesis stimulating agent 
ESR electron spin resonance 
ESRD end-stage renal disease 
GFR glomerular filtration rate 
Hb hemoglobin 
hCRP high sensitivity C reactive protein 
HD hemodialysis 
HDF hemodiafiltration 
HF hemofiltration 
HIF hypoxia inducible factor 
HIP heme iron polypeptide 
HMW high molecular weight 
ID iron-dextran 
IG iron-gluconate 
IM intramuscular 
IS iron-sucrose 
IV intravenous 
LMW low molecular weight 
MDA malondialdehyde 
MPO myeloperoxidase 
MW molecular weight 
NTBI non-transferrin bound iron 
PD peritoneal dialysis 
PO per os 
RES reticuloendothelial system 
SC subcutaneous 
SFP soluble ferric pyrophosphate  
TEAC trolox equivalent antioxidant capacity  
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!"#$%&'%"()"*+$,-.//0."
" ""
 
1 
PROLOGUE 
 
 
“I WILL FOLLOW that system of regimen which, according to my ability and judgment, I consider for 
the benefit of my patients, and abstain from whatever is deleterious and mischievous.”  
 
                                                      Hippocrates. The Oath; 5th Century B.C. 
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INTRODUCTION 
In this thesis, the etiology, pathophysiology and 
management of renal anemia will be reviewed 
with special emphasis on iron metabolism and 
iron treatment.  
Natural history  
In 1836, Richard Bright, in legendary notes on 
his patients, commended on the characteristic 
sign of renal anemia as “a progressive fading of 
the healthy colors of the countenance" 1. This 
condition, later described as normocytic, 
normochromic anemia, is almost an inevitable 
complication of severe renal failure. It is 
hypoproliferative in nature, with reduced 
reticulocyte count 2, 3 and progress in parallel 
with the reduction in renal function 4-6. However, 
the hemoglobin level is usually within the normal 
reference interval as long as the GFR is above 30 
mL/min, but, in diabetes, anemia can develop 
earlier, or when GFR falls below 45 mL/min 7.  
Definition 
According to The World Health Organization 
(WHO), the definition of anemia in general is a 
hemoglobin value below 130 g/L for males and 
120 g/L for non-pregnant women 8. However, 
great variability exists, depending, for example, 
on the level of altitude inhabitation. According to 
American and European guidelines, the definition 
of anemia in the CKD population is a 
hemoglobin level < 120 g/L in an adult female 
patient and < 135 g/L in an adult male patient 9, 
10. The diagnosis of renal anemia is by exclusion 
and it is recommended to initiate anemia work-up 
when hemoglobin falls below these limits. 
Etiology 
The etiology of anemia in patients with renal 
failure is complicated and multifactorial 11. The 
main cause is inadequate production of 
erythropoietin by the diseased kidneys 12-14 but 
other factors, such as derangements in iron 
regulation, significantly contributes to the 
development of renal anemia.  
Erythropoietin 
Interstitial cells, located in the peritubular 
capillary bed of the kidneys, are the main site of 
erythropoietin (EPO) production 15-17. In 
addition, some extrarenal production can occur in 
certain situations, mainly by the hepatocytes 18, 19. 
Normally, the production is regulated by a 
feedback mechanism involving an oxygen sensor 
that monitor the oxygen level in the vicinity of 
the EPO producing cell. 
The key mediator in this system is hypoxia-
inducible factor (HIF), a transcription factor 
produced in the kidney and the liver 20. Hypoxia 
leads to increased level of HIF by stimulating the 
production and inhibiting the degradation, which 
in turn stimulates EPO production 21. 
Furthermore, new evidence has been provided 
that HIF plays a more general role in cellular 
adaption to hypoxia, involving even the 
regulation of iron metabolism genes, such as the 
hepcidin gene, supporting a role for HIF in the 
coordination of EPO synthesis with iron 
homeostasis 20.  
The mechanisms behind renal anemia are not 
entirely understood.  The explanation is not 
simply that the EPO production falls secondary 
to cell damage, because serum EPO is often 
normal or slightly elevated in renal failure, even 
in patients with ESRD 4, 22. However, in 
comparison to anemic patients with normal 
kidney function, EPO production in patients with 
renal failure does not respond adequately to the 
fall in hemoglobin 4, 23. Accordingly, the EPO 
levels are lower than in patients with similar 
degree of anemia, but without renal failure 22. 
Thus, it seems that the regulation of EPO 
production is impaired and the EPO-producing 
cells are unable to respond adequately to the 
signals triggered by the oxygen tension. 
A well-known observation is that patients with 
renal failure, staying at high altitude, have 
increased EPO production and lower ESA 
requirement 24, 25. This is interesting and it has 
been implied that hypoxia can trigger an 
extrarenal EPO production or activate unused 
production capacity of EPO in the deceased 
kidneys. The facts that hypoxia induces HIF 
2%$3+4$.+"0,"5$.36"7.$483!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!"
 
;< 
production and that a pharmacological 
enhancement of HIF in patients with ESRD leads 
to several-fold increase in EPO production, 
further support the theory that the inappropriately 
low production of EPO in renal anemia is a result 
of desensitization of the oxygen-sensing 
mechanism rather than a destruction of the cells 
26. 
Iron  
Normally, iron homeostasis is beautifully adapted 
to the body’s requirements. By evolution, 
systems regulating iron absorption, iron transport 
in blood and iron storage in cells have developed. 
On the other hand, no mechanisms for iron 
excretion exists 27-29, so the only way to avoid 
toxic iron overload is to adjust iron absorption. In 
the normal process of erythropoiesis, iron is 
delivered to the erythroblasts as needed to 
maintain adequate hemoglobin synthesis. In renal 
failure, iron regulation is disordered; the 
absorption is decreased and iron is often blocked 
in stores, which can lead to the development of 
absolute and/or functional iron deficiency 30. 
Moreover, in patients on chronic hemodialysis, 
iron loss, due to frequent blood samples and 
sequestration of red cells in dialysis membranes 
and tubing, has been calculated to around 1000 
mg/year 31. 
Hepcidin 
The discovery of hepcidin about a decade ago 32, 
33 has brought a new light on the pathogenesis of 
iron deficiency in renal anemia. Hepcidin, a 25 
amino acid peptide hormone (25-hepcidin) 
produced by the hepatocytes, is a key regulator of 
iron homeostasis 34. It binds to and induces 
internalization of ferroportin, a transmembrane 
iron-channel present in enterocytes, macrophages 
and hepatocytes 35. This hinders iron transport 
out of cells. Thus, increased hepcidin levels can 
lead to true iron deficiency by decreasing 
intestinal iron absorption, and to functional iron 
deficiency by blocking iron release from iron 
stores. Hepcidin production is induced by 
inflammation and iron overload 33, 36, two 
common findings in CKD patients. Further, since 
the kidneys normally eliminate hepcidin, a 
successive accumulation occurs in parallel with 
the fall in GFR 37 and patients reaching ESRD 
have high serum hepcidin concentrations 37-40.  
Accordingly, abnormally high hepcidin levels 
can, at least in part, be the explanation for the 
reduced iron absorption described in both PD and 
HD patients 41, 42. In addition, iron absorption in 
HD patients is further reduced by concurrent 
inflammation, which also supports the 
involvement of hepcidin 42. The fundamental role 
of hepcidin in the pathogenesis of renal anemia is 
illustrated in figure 1. 
  
Uremic toxins 
The retention of various waste products in uremia 
can, in different ways, lead to anemia. They are 
probably responsible for the shortened life span 
of red blood cells (from normal 120 to 60-90 
days), which has been documented in ESRD 12, 
43. Further, serum extracted from uremic patients 
has been found to suppress erythropoiesis in a 
dose-dependent way 44, 45 and this suppression 
was not found with creatinine or urea. This 
indicates the existence of a uremic toxin, or 
toxins, that act as a “suppressor” in the bone 
marrow. In addition, increased erythropoiesis 
following start on dialysis supports the role of 
uremic toxins in the pathogenesis of renal anemia 
(see below). It is not clear which uremic toxins 
are involved but it has been suggested that they 
are in the middle molecular weight class and 
Figure 1. The central pathogenetic role of hepcidin in 
the development of renal anemia.  
 
Uremia  
Inflammation  
Absorption 
Erythropoiesis  Iron deficiency 
Iron trapped in stores 
Hepcidin  
GFR  
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probably involve substances such as various 
polyamines 7.  
Other causes 
Several other factors can contribute to anemia in 
renal patients. Malnutrition, hyperparathyroidism 
and chronic inflammation are best documented, 
conditions that are commonly found in uremia 
and well-known suppressors of erythropoiesis 7, 
46. 
Clinical manifestations 
Renal anemia is associated with deprived general 
health, manifesting as fatigue, loss of libido, 
dizziness, shortness of breath, reduced exercise 
tolerance and poor quality of life 11, 47. In general, 
these symptoms occur when hemoglobin is less 
than 100 mg/L 11. Further, anemia has been found 
to be a risk factor for left ventricular growth 48 
and heart failure 49. These two conditions are 
strong predictors of mortality and are frequently 
present in patients starting on long-term dialysis 
50. Indeed, Foley et al found that among 
hemodialysis patients, anemia was independently 
associated with mortality 51 and it seems that a 
hemoglobin level around 100-110 is critical as 
mortality increases exponentially with fall in 
hemoglobin beneath this level 52. 
Treatment 
The core treatment of renal anemia is to fuel 
erythropoiesis by regular injections with 
erythropoiesis stimulating agents (ESAs) and to 
secure sufficient iron availability for proper 
erythropoiesis 9, 53.  
Erythropoietin 
Historical notes 
In 1960, erythropoietin was obtained from 
plasma of anemic sheep 54 and a decade later 
from urine of anemic humans 55. It was then 
purified 56 and finally cloned, making it possible 
to produce biologically active recombinant 
human erythropoietin (rHuEPO) 57. In 1986, 
Winearls et al. reported that injections with 
rHuEPO effectively increased the hemoglobin 
level in patients on chronic hemodialysis, 
keeping them off the otherwise needed blood 
transfusions 58 and, in 1987, Eschbach and 
colleagues further confirmed this impressive 
response by using the first generation of ESA, 
epoetin alpha, in patients on chronic 
hemodialysis 59.  
Mechanism of action 
Endogenous erythropoietin (EPO), as well as all 
currently available erythropoiesis-stimulating 
agents (ESA), binds to the EPO receptors found 
on the cell membrane of colony-forming-unit 
erythroid cells and erythroblasts in the bone 
marrow 60. By activation of these receptors, EPO 
prevents apoptosis of these cells, making them 
able to continue the differentiation toward mature 
erythrocytes 61-64.  
Administration  
The response to ESA is dose-dependent 59 but the 
dose-variation is huge, both between individuals 
65 and within a given individual 66. In 
consequence, frequent individual dose-
adjustments are required to keep the hemoglobin 
value within the recommended interval 67, which, 
in patients on chronic hemodialysis treatment, is 
between 110 and 120 g/L 10, 68. Several agents are 
on the market and differ in terms of molecular 
structure, receptor affinity, serum half-life, 
bioavailability, and potency 60. Together, these 
characteristics shape distinctive dosing schedules 
for each agent, but otherwise, no clinically 
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Figure 2. An overview of the history of erythropoietin 
in clinical medicine.  
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important variations between these agents have 
been confirmed 10.  
Numerous factors can affect ESA response 46, 
69, such as the pharmacological property of the 
agent or health status of the patient. Thus, for 
ESA with short half-life, IV administration 
results in higher ESA demand than SC injections 
70, 71. Further, more ESA is needed in case of 
inflammation and infection 72, 73, iron deficiency 
74, malnutrition 75 and insufficient dialysis dose 
76. Taken together, it can be stated that ESA 
response reflects the overall health status of the 
patient and, indeed, high ESA resistance is 
associated with increased mortality and 
morbidity 77.  
Side effects 
Treatment with ESA is generally safe and side 
effects are few. The most serious, but rare, 
complication, is the development of EPO-
antibodies, which results in pure red cell anemia 
11. Hypertension has also been described 78, in 
particular if hemoglobin rises quickly, and is 
usually seen within the first 90 days of treatment 
11. In addition, large ESA doses may be 
hazardous, leading to increased risk of 
cardiovascular events 79-83. 
Clinical outcomes 
The benefit of ESA treatment on reducing the 
need for transfusions, and thereby decreasing the 
risk of immunologic sensitization, infections and 
iron overload, is well documented. Further, 
significant improvements in quality of life and 
functional parameters, such as aerobic capacity, 
cognitive function and sexual function, has been 
noted with ESA treatment 65, 84-88. Surprisingly, 
no improvement in quality of life was noted in 
the TREAT trial 80, comparing ESA with placebo 
in 4038 diabetics with CKD not on dialysis. In 
addition, randomized clinical trials showing 
reduced mortality with ESA treatment are lacking 
11.  
The optimal hemoglobin target in CKD 
patients is controversial. Judging from studies on 
the CKD population, no clear benefit appears to 
be associated with hemoglobin levels higher than 
110 g/L. Thus, in clinical studies, the beneficial 
effect of ESA on left ventricular hypertrophy was 
mainly seen with hemoglobin target of 100-110 
g/L 89, 90 and in observational studies, mortality 
descended with increasing hemoglobin 
concentrations up to a level of 100-110 g/L 51, 52. 
In attempt to answer the question if further 
increase in hemoglobin is beneficial, several 
prospective randomized trials have been 
conducted. Briefly, the results of these studies 
have been disappointing. Patients randomized to 
normal hemoglobin levels (130-150 g/L) have 
been found to have increased rate of 
cardiovascular complications and mortality 
compared to patients randomized to low 
hemoglobin levels (100-115 g/L) 79-82. The 
reason for this is not clear, but the results from a 
secondary analysis on data from the CHOIR 
study 81, where the poor outcome in the high 
hemoglobin group were restricted mainly to 
patients with high ESA resistance 83, argue for a 
mechanism involving high ESA doses rather than 
the hemoglobin value per se. Thus, the response 
to ESA appears to be an indicator of the general 
physical condition and patients that respond to 
ESA, even though high doses are needed, have 
lower mortality risk than non-responders 91. Still, 
the general recommendation is to keep the 
hemoglobin level beneath 120 g/L 10, 68. 
Oral iron salts  
Historical notes 
In Greek Mythology, Melampus the seer advised 
Phylacus to cure his son, Iphiclus, from 
impotence by having him ingest iron melted from 
his broadsword. After this original report, many 
centuries escaped before iron was introduced as 
medicine. In 1640 Lazarus Riverius, a physician 
to the France king, Louis XIV, recommended, 
“steel dissolved in wine” as a treatment for 
chlorosis, a disease of young woman, considered 
a kind of  “love sickness” but later known as iron 
deficiency anemia 92. In 1832, another 
Frenchman was the first to introduce ferrous iron 
as pills for treatment of anemia 93 and thereafter, 
many different oral iron salts have been 
developed. 
Side effects 
Various gastrointestinal symptoms, like nausea, 
constipation and diarrhea, are common side 
effects with oral iron treatment. Mostly, this is 
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due to a release of the reactive ferrous iron 
(Fe2+), which can provoke various reactions in 
the mucous membrane. The incidence of these 
side effects is high, or 47 % in healthy 
individuals 94 and at least 35 % in CKD patients 
95, 96.  
Clinical outcomes 
To evaluate the effect of oral iron in renal 
anemia, one has to distinguish between different 
patient categories. In general, iron requirement 
increases in following order: CKD not on dialysis 
> PD > HD. Moreover, additional iron is often 
needed in patients requiring ESA.  
In most CKD patients not on dialysis, oral 
iron, if tolerated, seems to be sufficient treatment 
for proper erythropoiesis 97 even though these 
patients require treatment with ESA 96, 98-100. 
PD patients are not as well investigated as the 
HD population. However, when ESA is needed, 
treatment with oral iron is only sufficient in a 
minority of patients 101. In HD patients receiving 
ESA treatment, short term treatment with oral 
iron has resulted in increased or stable 
hemoglobin levels, but iron stores, estimated by 
serum ferritin, decreased over time 96, 102-104.  
Oral heme-iron 
Meat and food products from blood components 
are rich in heme iron, an organic iron, which, in 
contrast to inorganic iron salts, is absorbed via a 
unique heme receptor in the intestinal cell 105-107. 
Unlike inorganic iron, heme iron absorption is 
not affected by simultaneous food intake and its 
absorption is approximately 10 times higher than 
for inorganic iron salts 108.  
Tablets with concentrated heme iron for 
human use have been produced and marketed as 
a nutritional supplement. One such compound, 
heme iron polypeptide (HIP), has been found to 
have a high bioavailability, 23 times better 
absorption than iron fumarate, and no 
gastrointestinal side effects 109. One clinical trial 
has been conducted on HIP effects in patients on 
chronic hemodialysis with promising outcomes. 
In that study, Nissenson and colleague found that 
during 6 months, HIP could successfully replace 
IV iron in majority of patients and, interestingly, 
treatment with HIP was associated with lower 
ESA demand 110. 
Intravenous iron 
Historical notes 
Parenteral iron was first introduced in the early 
20th century, when Heath and colleague 111 
injected ferric hydroxide solutions into patients 
with hypochromic anemia. They observed a rise 
in hemoglobin that was proportional to the 
amount of iron administered. On the other hand, 
severe toxic reactions were noted, likely due to 
the instability of the compound, permitting iron 
to dissociate into the circulation. In 1947, Nissim 
introduced an iron complex for IV injection, 
containing a carbohydrate shell (saccharide) 
around a ferric iron core and concluded that this 
form of iron was safer and more suitable for 
parenteral administration 112. In 1954, high 
molecular weight iron-dextran (HMW-ID) was 
introduced for IM and IV use. It was found to be 
stable and side effects were few. However, 
severe anaphylactic reactions could occur, 
leading to the cautioning against use of parenteral 
iron except under extreme clinical conditions. 
HMW-ID was the only parenteral iron product 
available until the 1990s and a minor product 
until the introduction of epoetin alpha, the first 
ESA, in 1989 65. Since then, different iron-
carbohydrate complexes have been developed, 
such as low molecular weight iron-dextran 
(LMW-ID), iron-gluconate, iron-sucrose, 
ferumoxytol, iron-carboxypolymaltose and iron-
isomaltoside. 
Chemical properties 
All IV iron agents consist of a ferric iron core 
surrounded by a carbohydrate shell, which 
stabilizes the complex and slows iron release. IV 
iron agents differ in terms of core size and 
identity of the shell 113. These dissimilarities 
determine not only different pharmacological 
properties of the agents such as stability, iron 
release and maximum tolerated dose but also 
various side effects and safety profiles 114. 
Mechanism of action 
After IV injection, most of the iron complex is 
removed from the circulation by phagocytes of 
the reticuloendothelial system located in the 
liver, spleen, and bone marrow. Within 
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phagocytes, iron is released and either stored in 
ferritin or released for extracellular transport by 
transferrin, which delivers iron to transferrin 
receptors on the surface of erythroblasts in the 
bone marrow 113.  
Side effects 
In general, treatment with IV iron agents is safe 
and well tolerated 115. However, side effects can 
arise, either from iron released from the ferric 
iron core, or from the carbohydrate shell. Further, 
there is a possibility of long-term adverse effects 
due to iron overload. 
Complications related to iron 
Adverse reactions occur if the iron complex is 
unstable, allowing labile iron to appear in the 
circulation, which, in theory, only can happen if 
iron release from the complex overrides the total 
plasma iron binding capacity. This has been 
investigated in vitro, by looking at different IV 
iron agents and their ability to directly donate 
iron to transferrin. These studies showed that 
their stability depends on the type of the 
carbohydrate shell and the size of the IV iron 
complex 116, 117. Thus, direct iron release was 2.5-
5.6 % with the following progression IG > IS > 
ID. This “labile” fraction has been a matter of 
concern, because it can induce various oxidative 
reactions. Unbound ferric iron (Fe3+) is 
potentially hazardous to the body as it could 
rapidly be reduced to its ferrous state (Fe2+) by 
any bioreductants available, such as ascorbic 
acid. Ferrous iron is toxic and can catalyze 
reactions associated with oxidative tissue 
damage. For example, it can mediate the 
formation of the noxious hydroxyl radical (HO#) 
via the Fenton reaction 118:  
 
Fe2+ + H2O2  "  Fe3+ + HO
#  + HO # 
 
Several studies have reported unbound iron in 
the circulation following IV iron-sucrose 
injections 119, 120. However, the nature of the iron 
measured is controversial, and it is a possibility 
that the iron assay used has in fact measured iron 
extracted directly from the circulating iron 
complex. However, various “footsteps” of 
catalytically active iron have been observed in 
the circulation following IV iron injections. 
Mostly, an elevation of various oxidative stress 
markers, such as markers of lipid peroxidation, 
DNA damage 121 and protein oxidation have been 
noted 122. 
In CKD patients, oxidative stress induction 
has been seen mainly following IS injection 121, 
123-136 but also following administration of IG 137-
140 and ID 130,141. This is especially worrying 
because increased oxidative stress has been 
linked to the severe cardiovascular disease found 
in patients with ESRD 142-144 and, indeed, a 4 
year prospective follow-up study on 94 HD 
patients reported that oxidized LDL was an 
independent predictor of mortality 145.  
Other potential associations between IV iron 
and vascular disease have been postulated. In 
healthy individuals, endothelial dysfunction has 
been reported following IS injection 132, 146, in 
CKD patients, IV iron-polymaltose injection has 
been shown to increase fibroblast growth factor 
23 (FGF-23), a pathogenic factor for 
arteriosclerosis 147, 148 and in iron-dextran loaded 
mice, accelerated thrombus formation after 
arterial injury has been observed149. Moreover, a 
link between labile iron and vascular 
calcifications, either directly or via oxidative 
stress, has been noted in vitro 150 and NTBI has 
been found to stimulate the expression of 
vascular adhesion molecules and promote 
monocyte recruitment to vascular endothelium 
151-153. These findings further support the concept 
of iron-induced endothelial injury. 
The above-mentioned studies have evaluated 
the toxicity of IV iron by measuring changes in 
extracellular markers. Recently, a study on 10 
HD patients reported increased levels of 
intracellular reactive oxygen species following IS 
and ID injection 154. Interestingly, the same study 
also reported an elevation in IL-6 and TNF-$, 
indicating iron-induced inflammation.  
Several other side effects of IV iron have been 
described, such as nephrotoxicity, iron overload 
and increased susceptibility to infections. 
Agarwal et al. raised concern about potential 
nephrotoxicity 123. They found transient 
proteinuria, enzymuria and tubular damage 
following IV IS injection and postulated a 
mechanism involving increased oxidative stress.  
Iron overload is a possibility during long-term IV 
iron treatment. This is worrying because, in HD 
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patients, the accumulated iron dose over time, 
has been associated with the level of 
atherosclerosis 155, risk of hospitalization 156 and 
death rate 156-158. Finally, a link between iron 
treatment and increased risk of bacterial infection 
has been suggested. Iron is a growth factor for 
bacteria 159 and high iron load in HD patients has 
been reported to inhibit neutrophil function 160, 
161. However, clinical evidence linking IV iron 
treatment to dialysis-related infections is lacking 
162.  
Complications related to carbohydrates 
Serious, life-threatening allergic reactions may 
occur during treatment with iron-carbohydrate 
complexes. These reactions, evoked by epitopes 
in the carbohydrate shell, have primarily been 
noted with high-molecular weight ID and are 
rarely seen with the IV iron agents used today 115.  
Clinical outcomes 
In comparison with oral iron, IV iron is superior 
regarding hemoglobin response in patients on HD 
and PD 99, 163. In this context, superior means 
faster hemoglobin response, higher hemoglobin 
value and lower ESA dose. On the other hand, in 
CKD patients not on dialysis and not treated with 
ESA, IV iron is not superior to oral iron 
treatment 97 and even though these patients 
require ESA, the benefit of IV iron compared to 
oral iron is small 98, 99 or non-existent 96, 100. 
Treatment with vitamin C 
Some efforts have been made in treating 
functional iron deficiency by using ascorbic acid 
to mobilize iron from the stores 164. Studies on 
HD patients with refractory anemia and 
hyperferritinemia have shown that IV ascorbic 
acid has a beneficial effect, significantly 
increasing transferrin saturation and hemoglobin 
levels 165, 166. Moreover, a decrease in serum 
ferritin and an increase in the response to ESA 
have been noted, suggesting iron mobilization 
from the tissue stores. However, controversies 
surrounding treatment with IV ascorbic acid 
exist.  Some authors have not found any 
beneficial effect at all 167 and there is concern 
regarding the safety of this treatment.  One 
potential side effect is hyperoxalatemia and 
another is induction of oxidative stress. Sudden 
high doses of intravascular ascorbic acid in a 
patient with high iron load may reduce the ferric 
iron to catalytically active ferrous iron, capable 
of inducing oxidative reactions. This pro-
oxidative effect of ascorbic acid has been 
observed in vitro with plasma from HD patients 
168 and in serum of iron-loaded animals 169. 
Moreover, in a study in HD patients, orally 
administrated ascorbic acid was found to increase 
lipid peroxidation 170. 
Renal replacement therapy 
It is not surprising that renal anemia is corrected 
by successful kidney transplantation 23. In a five 
years follow-up study after transplantation, 
anemia was cured in the majority of patients and 
even erythrocytosis occurred in 18 % 171. 
However, with time, approximately 30 % of the 
patients developed anemia 171, 172. 
When CKD patients start on dialysis, a 
significant improvement of erythropoiesis has 
been observed. This is most likely due to removal 
of uremic toxins (“erythroid suppressors”) by the 
dialysis process. Thus, in 34 peritoneal dialysis 
patients, DePaepe et al. found a significant 
increase in hemoglobin during the first 6 months 
after initiation of the treatment 173. Similarly, 
Radtke et al. studied 42 ESRD patients and 
observed better hematocrit and lower serum 
erythropoietin levels after start of hemodialysis 
174. 
Before the era of ESA, it was noted that the 
hemoglobin level increased in patients 
transferred from HD to PD 175. Further, when 
comparing these two dialysis modalities, a milder 
degree of renal anemia has been observed in the 
PD population 176, 177. Thus, in a large register 
study, the proportion of patients requiring ESA 
was 25 % in PD compared to 80 % in HD and the 
ESA dose was 50 % lower in the PD population 
176. The possible reason for this is that blood loss 
is less marked and residual renal function is 
better preserved in PD 176, 178. Indeed, residual 
renal function has been observed as an important 
predictor of the severity of renal anemia, both in 
the PD 179 and HD 180 population. The dialysis 
dose is also important since inadequate 
hemodialysis is associated with suboptimal 
response to erythropoietin therapy 181. Further, 
increased dialysis dose has been associated with 
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reduced ESA need 76, 182. On the other hand, in 
patients receiving hemodialysis three times a 
week, the benefit of increasing the hemodialysis 
dose is only present up to a level of 
approximately 1.3 in Kt/V. Increasing dialysis 
dose beyond this level seems to have no effect on 
the severity of renal anemia 69, 183. The reason for 
this is not clear.  
Whether different dialysis modalities, such as 
hemodiafiltration (HDF) and hemofiltration 
(HF), are superior to HD in treating renal anemia 
is a matter of debate. Some authors have 
described better anemia control with HDF 184-187 
while others have failed to find such an effect 188, 
189.  Thus, good evidence indicating any benefit 
of convectional dialysis treatments on renal 
anemia is lacking 190, 191. 
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AIMS OF THE THESIS 
The general purpose of this thesis was to study 
three different issues in the treatment of renal 
anemia; (1) potentially toxic side effects of IV 
iron, (2) impact of convective hemodialysis on 
iron homeostasis and (3) ESA dose-sparing effect 
of change in ESA administration praxis.  
 
The specific aims were: 
• To evaluate if electron spin resonance 
(ESR) spectroscopy could be used to 
address the issue of iron toxicity by 
measuring free iron appearance and acute 
oxidative stress following IV iron 
injection (Paper I). 
• To explore possible changes in markers of 
oxidative injury in the circulation 
following iron injection (Paper I and II).  
• To investigate if any difference exists 
between iron-sucrose and iron-dextran 
regarding release of free iron and 
induction of oxidative reactions       
(Paper II). 
• To answer the question if there is any 
clinically relevant disparity between two 
different hemodialysis modalities, HD 
and HDF, especially concerning iron 
homeostasis and erythropoietin or iron 
demand (Paper III). 
• To study if the frequency of ESA dose-
adjustments has effect on ESA 
requirements and hemoglobin response 
(Paper IV). 
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SUBJECTS AND METHODS 
Subjects 
All clinical data in this thesis are collected from 
64 patients with end stage renal disease, of which 
13 participated in more than 1 study. During the 
respective study periods, all patients were 
receiving regular dialysis treatment and their 
clinical condition was stable. The demographic 
data are described in detail in the respective 
studies. 
Study designs 
Paper I 
This study is a prospective, open label, 
hypothesis-testing study. It was designed to 
investigate the release of intravascular “free” iron 
and acute oxidative stress following IV injection 
of 100 mg iron-sucrose. Two experiments were 
conducted, one with and one without ongoing 
dialysis. Blood samples were collected before, 
10, 30 and 60 minutes after IV iron injections.  
Paper II 
This study was designed to compare two 
commercially available IV iron formulations 
regarding intravascular “free” iron release and 
induction of acute oxidative stress. It is an open 
label, prospective, non-randomized, and cross-
over, explorative study. Blood samples were 
drawn before and 10 minutes after IV injection 
with iron sucrose, and four weeks later the 
procedure was repeated with iron-dextran.  
Paper III 
This study was designed to compare conventional 
hemodialysis and on-line hemodiafiltration 
regarding dialysis-related symptoms as well as 
various biochemical parameters. It is a 
prospective, randomized, participant-blinded, 
partially observer-blinded and cross-over 
explorative trial. Study visits took place before as 
well as after 30 and 60 days on respective 
treatment. 
 
Paper IV 
This is a retrospective, hypothesis-testing study. 
It was designed to compare ESA use and 
predictors of ESA requirement in two equivalent 
periods before and after a change in ESA 
administration praxis. Data from the local 
dialysis database were assembled for statistical 
analysis. 
Biochemical analyzes 
Routine analyzes 
With the exception of NTBI, 25-hepcidin, Il-6 
and markers of oxidative stress, all biochemical 
analyzes were performed as accredited routine 
clinical laboratory tests by the Central Laboratory 
of Sahlgrenska University Hospital. 
Plasma iron 
Analysis of total plasma iron was performed by a 
standard method at the clinical laboratory. This is 
a colorimetric assay based on iron binding by 
ferrozine 192.  
Electron spin resonance spectroscopy 
In Paper I and II, the technique of electron spin 
resonance (ESR) was used to analyze NTBI and 
AFR (see below). Because this is not a 
widespread method in clinical medicine, the 
basic principles will be briefly explained. 
ESR, aka electron paramagnetic resonance 
(EPR), is a very robust and sensitive method for 
characterization and quantification of substances 
with unpaired electrons 193. The method is based 
on the physical properties of an electron, being a 
charged particle spinning around its axis. This 
spinning causes the electron to behave like a 
small magnet, which could be compared the 
earth’s rotation, creating a magnetic field at its 
poles. For any given electron in any given 
substance, the probabilities for clockwise and 
counter-clockwise rotation around the axis are 
equal. Thus, these two rotational energy states, or 
spin states, are energetically equivalent in the 
absence of a magnetic field. However, if a 
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constant external magnetic field is applied, the 
electrons will align either parallel or anti-parallel 
with that field. The parallel state is associated 
with a lower energy level than the anti-parallel 
state. The energy difference between the two 
levels is proportional to the field strength, B0, of 
the external magnetic field according to the 
following equation: 
 
!E = ge"bB0 
 
wherein ge (the g-factor) and $b (the Bohr 
magneton) are fundamental constants of the 
electron. The lower energy level (parallel spin) 
tends to be heavier populated than the higher one. 
If electromagnetic radiation with energy 
corresponding to: 
 
h# = ge"bB0 
 
(the resonance condition) is introduced into the 
system, transitions from the lower to the higher 
level can be induced. These transitions, each at 
the prize of an amount of energy equivalent to 
h%, can be measured as an absorbance of energy 
by the system under study, and this forms the 
basis of the powerful quantitative and qualitative 
analyses performed with ESR.  
It is important to note that only substances 
containing at least one unpaired electron, 
typically free radicals end certain metal 
complexes, can be detected by ESR. This is due 
to the fact that electrons have a strong tendency 
to form pairs with opposite spins. Such an 
electron pair is magnetically neutral, unaffected 
by the external field B0 and, hence, ESR-silent. 
Since the vast majority of substances occurring in 
biological systems do not have any unpaired 
electrons, ESR is an extremely powerful tool for 
detecting free radicals, such as ascorbyl radicals, 
or metals, such as iron compounds, even in very 
complex systems like blood or biological tissues, 
without the need for extensive sample treatment. 
Typical magnetic fields used for the studies 
described herein are in the order of 0,3–0,4 Tesla, 
and the electromagnetic energy absorbed by the 
unpaired electrons is typically in the microwave 
range, with a frequency of 9–10 GHz. 
Quantitative information about absorbing 
substances in the sample is gained via the 
amplitude of the signal. Qualitative information 
is gleaned from the fact that different substances 
present a different magnetic environment to any 
unpaired electron, mainly due to the magnetic 
fields caused by orbital motions of all other 
electrons in the molecule. This means that the 
external magnetic field is always either 
counteracted or augmented by a local magnetic 
field, varying in strength and direction for each 
type of molecule. Thus, in order to satisfy the 
general resonance condition (h# = ge"bB), 
where B is a constant equal to Blocal + B0, the 
external field B0 has to be adjusted slightly to a 
unique value for each substance.  
The main drawback of ESR in a clinical 
setting, even though the method is powerful and 
sensitive, is that the equipment is sophisticated, 
expensive and not widely available. 
Non-transferrin bound iron 
NTBI was measured essentially as described by 
Kozlov et al. 194. In brief, plasma was mixed with 
desferrioxamine (DFO) and incubated for 15 min 
in room temperature. During this period, NTBI in 
the sample is chelated by the added DFO and 
quantitatively oxidized to Fe(III). The samples 
were then filtrated to eliminate any interference 
from iron-containing proteins (transferrin, 
ceruloplasmin, etc.). Then, each sample was 
carefully frozen in liquid nitrogen and ESR 
spectra were recorded using an X-band 
spectrometer. The corresponding concentration 
of DFO-chelated iron was obtained from a 
standard curve consisting of different 
concentrations of ferrous ammonium sulfate 
[(NH4)2Fe(SO4)2] (figure 3.) 
 
 
Figure 3. The standard curve for the ESR determination 
of DFO-chelated iron. 
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Markers of oxidative stress 
Ascorbyl free radical 
The measurement of plasma AFR was made by 
ESR. The analysis was performed on pure plasma 
without any additional treatment of the specimen. 
Immediately after thawing the sample, the AFR 
signal intensity was measured with an X-band 
spectrometer. The AFR gives a characteristic 
two-peak signal and the mean peak-to-peak 
amplitude (figure 4) was calculated to determine 
the AFR concentration in the sample, using 1 µM 
Tempol as standard. 
 
Other oxidative stress and inflammation markers 
Estimation of lipoprotein oxidation was 
performed by measuring baseline levels of 
conjugated dienes in lipids extracted from LDL 
(BDC-LDL) by a spectrophotometric assay 195. 
Protein oxidation was determined by measuring 
protein carbonyl content with a 
spectrophotometric technique 196. The total 
antioxidant capacity was evaluated by a slightly 
modified spectrophotometric TEAC method 
(Trolox Equivalent Antioxidant Capacity) 197. 
Measurement of plasma myeloperoxidase (MPO) 
and Il-6 were analyzed with a commercially 
available ELISA kit according to the 
manufacturer's instructions. 
25-Hepcidin 
Serum 25-hepcidin was measured at 
Hepcidinanalysis.com, Nijmegen, the 
Netherlands by a combination of weak cation 
exchange chromatography and time-of-flight 
mass spectrometry 198. 
Statistical methods 
Statistical analyses were executed with the SPSS 
software package.  In all Papers, T-test or non-
parametric test (Wilcoxon, Mann Whitney) were 
used as appropriate for evaluation of differences 
between means, and Pearson’s or Spearman’s 
correlation was used to analyze association 
between two variables. In Paper I, a general 
linear model for repeated measures was used to 
explore changes in parameters over time. In 
Paper III, the Chi square test was used to 
compare frequency of symptoms between 
treatments. In Paper IV, a multiple regression 
model was used to analyze relationship between 
changes in predictors of ESA response and 
changes in ERI. 
The null-hypothesis was rejected if the p value 
was less than 0.05. 
Ethical considerations 
In Paper I (experiment 2), eight patients stayed at 
the dialysis unit for one additional hour after 
ordinary dialysis treatment. In all other 
experiments, ordinary individual dialysis 
schedules were used for each patient. No changes 
in medication were needed to make these studies 
and no additional drugs were given. Regarding 
iron treatment, all patients were on regular iron 
treatment at inclusion, and in Paper II patients 
receiving Venofer (IS) were given Cosmofer (ID) 
with a potential risk of allergic reactions. 
However, no such reactions were noted. An 
additional ethical issue is the blood loss 
associated with extra blood samples. 
Figure 4. The characteristic ESR spectra of AFR.  
The peak-to-peak amplitude (h) reflects the actual 
concentration in the sample.  
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SUMMARY OF MAIN RESULTS 
PAPER I 
Key findings 
1. A measurable amount of plasma NTBI was 
noted in hemodialysis patients and in healthy 
blood donors. 
2. The level of NTBI correlated significantly 
with the level of total iron. This was noted 
both pre-dialysis and following IV IS 
injection. 
3. After IV injection of IS, a burst of oxidative 
stress was noted. In particular, AFR 
dramatically increased. 
4. The increase in AFR was closely correlated 
to the increase in NTBI. 
5. When measured in vitro, 
a. Labile iron was released from IV iron-
carbohydrates, significantly more from IS 
than ID. 
b. Ascorbic acid was able to mobilize iron 
from IS but not from ID.  
 
 
Non-transferrin bound iron (NTBI). 
Before dialysis, all patients had a measurable 
level of NTBI in plasma (mean 1.6 µM) and it 
was closely correlated with total plasma iron 
(figure 5). In healthy blood donors, similar NTBI 
concentration was observed (mean 1.9 $M), but 
since total iron was not measured, a comparison 
of proportions of NTBI in healthy and patients 
was not possible. 
After IV injection of 100 mg IS, the plasma 
concentration of NTBI increased from 1.2 to 5.7 
$M and total plasma iron from 9.6 to 44.1 $M 
(table 1). Again, the levels of these parameters 
were strongly correlated (figure 6).  
Figure 5. The scatter plot and correlation between NTBI 
and total iron in pre-dialysis blood samples (p < 0.001). 
 
Figure 6. The scatter plot and correlation between 
total iron and NTBI in plasma 10 min after 
intravenous IV injection of 100 mg IS (p < 0.001). 
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Oxidative stress markers. 
Experiment 1. 
Ten minutes after IV injection of 100 mg IS, a 
significant increase in the plasma concentrations 
of AFR, MPO, protein carbonyl and BDC-LDL 
were noted (table 1). The enhancement was 40, 
22, 22, and 8 % respectively. During the same 
time, total antioxidant capacity (TEAC) 
decreased by 3.3 %, albeit not significant (p = 
0.06). 
 
Experiment 2 
Following IV injection of 100 mg IS, a parallel 
increase in AFR and NTBI was found (figure 7). 
After a peak at 10 minutes, the concentration 
gradually faded. However, compared to values 
before iron administration, a significant increase 
in both AFR and NTBI were still found one hour 
after the injection. The plasma concentrations of 
AFR and NTBI were very well correlated.  
Iron release from IV iron formulations in vitro 
During 60 minutes incubation of 500 µM IS (a 
concentration close to the maximum plasma 
concentration attained after injection of 100 mg 
IS) together with 10 mM DFO, 2.2 % of the iron 
in the IS complex was found to be loosely bound 
and chelated with DFO. Further, the amount of 
his labile iron was doubled when ascorbic acid 
was present. When the experiment was repeated 
with ID, the quantity of loosely bound iron was 
significantly lower (1.2%) and ascorbic acid did 
not mobilize iron from the ID complex. 
Table 1. Effects of IV infusion of 100 mg IS on iron parameters and various markers of oxidative stress   
              (mean ± SD). 
Figure 7. The plasma concentration (mean ± SEM) of 
NTBI and AFR during 60 min after IV injection of 100 
mg IS. ** = p < 0.01 compared to before iron 
injection, n=8. 
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Before 10 minutes after P value
iron infusion iron infusion
p-iron (!M) 9.6 ± 4.6 44.1 ± 11.6 < 0.001
p-NTBI (!M) 1.2 ± 0.5 5.7 ± 1.4 < 0.001
p-AFR (nM ) 202.5 ± 67.1 283.3 ± 108.7 < 0.001
p-MPO (ng/ml) 82.6 ± 39.0 101.1 ± 43.4 < 0.05
p-protein carbonyl (nM) 22.3 ± 5.9 27.1 ± 5.8 < 0.001
p-BDC-LDL (!M) 33.0 ± 9.4 35.7 ± 10.8 < 0.001
p-TEAC (!M Trolox) 5.13 ± 0.4 4.96 ± 0.5     n.s.
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PAPER II 
Key findings 
1. The iron analysis at our routine clinical 
laboratory directly measured 5.6 % of the 
iron bound in IS and 1.6 % of that bound in 
ID. 
2. Total iron and NTBI increased significantly 
more after injection of IS compared to ID.  
3. Acute oxidative stress was noted after IV 
injection of 100 mg IS but not after IV 
injection of 100 mg ID.  
Iron measurements in vitro 
The iron assay at the clinical laboratory is based 
on iron-chelation by ferrozine. This assay was 
used to measure iron in a solution of PBS and 
different concentrations of IS and ID. 
Significantly more iron was loosely bound in IS 
than in ID. Thus, ferrozine directly chelated 5.6 
% of the iron bound in IS and 1.6 % of that 
bound in ID.  
 
Iron measurements in vivo 
IV injection of IS and ID significantly elevated 
the levels of plasma iron and NTBI (table 2). 
However, both increased significantly more after 
IS than after ID or by 27.9 vs. 7.4 µM 
respectively (figure 8).  
Comparison between IS and ID regarding 
induction of oxidative stress. 
The levels of oxidative stress markers in plasma 
before and after IV iron injection are shown in 
table 2. After injection with IS, the concentration 
of AFR and protein carbonyl increased 
significantly, or by 29 and 19 % respectively. No 
significant changes were noted after injection 
with ID. Other oxidative stress markers were 
slightly, but not significantly, increased after iron 
administration.  
When changes in oxidative stress markers after 
IS were compared to changes after ID, only AFR 
increased significantly more after IS  (figure 9). 
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Figure 8. Changes in levels of plasma iron and NTBI 
10 minutes following IV iron injection (mean ± SD). 
* p < 0.05; ** p < 0.01. 
 
Figure 9. Changes in plasma levels of oxidative stress 
markers 10 minutes after IV iron injection (mean ± SD).  
** p < 0.01. 
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Table 2. Iron and oxidative stress parameters before and 10 min after injection of 100 mg IS, respectively 
100 mg ID (mean ± SD). 
Before After Before After
p-NTBI (µmol/L) 4.2 ± 1.8 6.2 ± 1.5 ** 3.9 ± 1.8 7.0 ± 2.8 ***
p-iron (µmol/L) 9.5 ± 3.2 16.9 ± 2.9 *** 10.6 ± 4.7 38.5 ± 8.4 ***
p-AFR (nmol/L) 58.7 ± 32.2 56.7 ± 28.5 55.7 ± 37.4 67.7 ± 44.6 ***
p-protein carbonyl (nmol/L) 19.1 ± 3.4 19.4 ± 4.1 19.4 ± 4.8 22.0 ± 4.8 *
p-BDC-LDL (!M) 26.7 ± 10.3 28.3 ± 11.6 27.4 ± 13.0 28.3 ± 13.1
TEAC (µmol/L TROLOX) 4.5 ± 0.7 4.4 ± 0.8 4.2 ± 0.8 4.3 ± 0.7
Iron-dextran Iron-sucrose
* p < 0.05; ** p < 0.01; *** p < 0.001 compared to before iron 
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PAPER III 
Key findings 
1. No significant differences between treatment 
with HD and HDF were found in: 
• Intra-dialysis complications 
• Inter-dialysis symptoms 
• Quality of life 
• Blood cell counts and hemoglobin 
• ESA and iron requirement 
• Inflammation and oxidative stress 
• Phosphate control 
2. Significant differences were found in: 
• Blood pressure, which was increased by 
HDF 
• The level of pre-dialysis s-albumin, which 
decreased by HDF 
• Clearance middle-weight molecules, which 
was improved by HDF, exemplified by: 
i. Iohexol 
ii. ß2microglobulin 
iii. 25-hepcidin 
3. A trend towards more normal iron 
homeostasis, with lower serum ferritin, was 
found with HDF. 
Dialysis-related symptoms and general health 
The frequency of intra-dialysis complications 
was similar during treatment with HD and HDF. 
Further, patients’ answers regarding dialysis-
related symptoms and general well-being were 
similar. Indeed, quality of life was considerably 
lower than in the general population in Sweden 
199, but no relevant differences between HD and 
HDF were noted (figure 10). 
Arterial blood pressure 
The arterial blood pressure was slightly higher 
during the last week of treatment with HDF 
compared to the same period on HD treatment 
(table 3). This was noted in all blood pressure 
measurements, but was only statistically 
significant in blood pressure measured in upright 
position before dialysis (p < 0.05). 
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Figure 10. Quality of life after 2 
months treatment with HD and HDF 
(mean). In comparison, average SF-
36 score in the general population 
in Sweden are shown. 
* p < 0.05 (HD compared to HDF) 
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Table 3. Systolic and diastolic blood pressure during the last three dialysis sessions on respective dialysis 
modality (mm Hg, mean ± SD).  
HD HDF HD HDF
Systolic
   Supine 157.5 ± 26.1 161.2 ± 29.9 157.1 ± 22.8 161.6 ± 25.1
   Standing 151.1 ± 26.1 156.4 ± 31.1 137.9 ± 18.4 143.0 ± 24.3
Diastolic
   Supine 86.4 ± 10.8  88.9 ± 12.6 85.3 ± 10.3 86.8 ± 12.8
   Standing 86.8 ± 12.6    90.1 ± 14.0 * 81.8 ± 9.5 85.1 ± 13.4
Pre-dialysis Post-dialysis
* p < 0.05 compared to HD 
Table 4. Hematological and chemical parameters at baseline, on day 30 and on day 60 in respective study 
period (mean ±SD). 
a = compared to baseline     b = compared to HD     * p < 0.05     ** p < 0.01     *** p < 0.001 
Day 0
Baseline HD HDF HD HDF
Hemoglobin (g/L) 116.1 ± 12.2 116.1 ± 7.5 115.6 ± 8.9 116.1 ± 8.4 115.1 ± 6.0
Mean corpuscular volume (x 10-15L) 97.1 ± 5.5 96.3 ± 5.0 97.9 ± 5.7 97.2 ± 5.7 98.0 ± 4.9
Leukocyte count (x 109/L) 8.1 ± 2.5 7.4 ± 2.1 7.5 ± 2.3 7.0 ± 1.8 a** 7.1 ± 2.3 a**
Thrombocyte count (x 109/L) 241 ± 76 232 ± 80 237 ± 75 234 ± 69 236.5 ± 83.1
s-sodium (mmol/L) 137.2 ± 3.2 137.7 ± 3.8 137.8 ± 3.3 137.3 ± 2.3 137.5 ± 2.4
s-potassium (mmol/L) 5.0 ± 0.9 4.8 ± 0.5 4.8 ± 0.6 4.9 ± 0.6 5.0 ± 0.8
s-calcium (mmol/L) 2.4 ± 0.2 2.4 ± 0.2 2.4 ± 0.2 2.4 ± 0.2 2.4 ± 0.4
s-phosphate (mmol/L) 2.0 ± 0.5 1.7 ± 0.5 1.7 ± 0.4 1.8 ± 0.4 1.7 ± 0.4
s-bicarbonate (mmol/L) 23.5 ± 2.0 24.3 ± 1.3 24.5 ± 1.7 24.2 ± 1.6 24.1 ± 2.3
s-creatinine (!mol/L) 748 ± 240 685 ± 199 a** 658 ± 209 a***, b* 688 ± 213 a** 671 ± 192 a**
s-BUN before dialysis (mmol/L) 21.9 ± 5.8 18.1 ± 4.7 a*** 16.3 ± 4.5 a*** 18.1 ± 4.5 a** 17.3 ± 3.8 a***
s-albumin (g/L) 34.8 ± 3.2 35.1 ± 3.0 34.9 ± 3.0 36.0 ± 2.9 34.3 ± 2.6 b**
s-ferritin (!g/L) 302 ± 141 311 ± 145 276 ± 119 311 ± 126 253 ± 95
s-hsCRP (mg/L) 11.2 ± 12.2 10.5 ± 9.5 9.3 ± 8.7 9.8 ± 10.2 9.6 ± 11.1
s-ß2microglobulin (mg/L) 30.6 ± 11.9 34.6 ± 12.0 24.9 ± 8.5 a***, b *** 34.6 ± 17.0 23.7 ± 8.1 a**, b***
Day 60Day 30
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Pre-dialysis variables 
The results of clinical chemistry analyses at 
baseline and during treatment with respective 
dialysis modality are shown in table 4. The only 
significant differences between HD and HDF 
after 30 and 60 days were lower level of 
ß2microglobulin, reflecting better clearance of 
this substance by HDF. At day 60, significantly 
lower levels of s-albumin and a trend towards 
lower levels of s-ferritin (p = 0.085) and larger 
MCV (p = 0.084) were found.  
Post-dialysis variables   
The results of post-dialysis serum analyses at day 
60 are shown in table 5. Markers of inflammation 
and oxidative stress were similar between 
treatments. On the other hand, a significant lower 
concentration of 25-hepcidin was found with 
HDF and it was closely associated with the pre-
dialysis ferritin value, as seen in figure 11. 
ESA and iron requirements 
No significant differences in ESA and iron 
consumption between treatment with HD and 
HDF were found. The variation was large and the 
mean doses of ESA and iron during the second 
month were slightly higher during treatment with 
HDF or 13275 ± 10850 IE/week compared to 
17300 ± 16667 IE/week with HD (p = 0.073). 
The mean IV iron dose during HD was 270 ± 205 
mg and 320 ± 237 mg during HDF (p = 0.357). 
Table 5. Post-dialysis markers of inflammation, 
oxidative stress and iron homeostasis on day 60 
with respective treatment (mean ± SD). 
 
HD HDF
s-interleukin 6 (pg/ml) 17.4 ± 17.0 18.1 ± 11.5
s-MPO (ng/ml) 90.1 ± 76.8 93.4 ± 59.9
s-protein carbonyl (nmol/l) 23.5 ± 4.4 23.1 ± 4.3
s-BD-LDL (!M) 44.4 ± 13.8 41.1 ± 13.3
s-TEAC (!M Trolox) 4.0 ± 0.6 4.1 ± 0.7
s-hepcidin (nM) 11.1 ± 5.4 6.9 ± 2.9 **
y = 0,0284x + 0,839 
R! = 0,497 
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Figure 11. Post-dialysis serum hepcidin plotted against 
pre-dialysis serum ferritin (p < 0.001). 
 
** p < 0.01 compared to HD. 
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PAPER IV 
Key findings 
1. After a change in ESA administration praxis, 
a 22.5 % decrease in ESA demand and 19.9 
% decrease in ERI were noted. 
2. In a multivariate regression model, the drop 
in ESA demand could not be explained by 
changes in well-known predictors of ESA 
response. 
ESA consumption and hemoglobin  
Figure 12 illustrates the mean ESA dose per 
week and the pre-dialysis hemoglobin level in 
each month during the entire follow-up. As seen, 
the drop in ESA dose after change of the ESA 
administration praxis did not have any 
considerable effect on the hemoglobin value. 
The mean ESA dose and ERI were 
significantly reduced in Period 2 compared to 
Period 1 (table 6). At the same time, mean pre- 
and post-hemoglobin values dropped by 1.1 and 
2.4 g/L, however, this reduction did not reach 
stitistical significance (p = 0.42 and 0.09). 
 
Predictors of ERI 
The levels of well-known predictors of ESA 
response are summarized in table 7.  
The transferrin saturation and dialysis dose, 
measured as dialyzed blood volume per dialysis 
session, was significantly increased in Period 2. 
The variation of other parameters before and 
after the change in ESA administration praxis 
was similar. When testing for associations 
between changes in ERI and changes in these 
predictors, a significant inverse correlation with 
changes in s-transferrin saturation, dialyzed 
blood volume and s-ferritin, was found (table 8).  
However, in a multivariate regression model with 
& ERI as outcome and & CRP, & albumin and & 
dialyzed blood volume as independent variables, 
none of these factors significantly predicted 
changes in ERI (table 9). S-ferritin and s-
transferrin were excluded in the model because 
of bidirectional relationship with ERI.  
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Figure 12. Hemoglobin concentration and ESA consuption during follow up (mean ± SEM), n =18. 
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Predictors of hemoglobin concentration 
Changes in transferrin saturation and changes in 
serum ferritin were correlated with changes in 
post-dialysis hemoglobin (p=0.02 and 0.04), 
while changes in ESA dose per week were not. In 
a multiple regression analysis, & post-dialysis 
hemoglobin as outcome and & transferrin 
saturation, & dialyzed blood volume, & CRP, & s-
albumin and & PTH as predictors, only changes 
in transferrin saturation turned out as an 
independent predictor (beta = 0.414, p value = 
0.019).  
Table 6. Erythropoiesis parameters during respective study period (Mean ± SD). 
 
 Period 1 Period 2 p value
Hemoglobin pre-dialysis (g/L) 117.0 ± 4.8 115.9 ± 5.1 ns
Hemoglobin post-dialysis (g/L) # 125.1 ± 4.7 122.7 ± 5.4 ns
IV iron consumption (mg per day) 5.1 ± 4.5 5.0 ± 3.9 ns
ESA dose (IU/kg/week) 186.5 ± 117.8 144.6 ± 126.4 < 0.01
ERI (IU/kg/week/g/dL) 15.1 ± 9.9 12.1 ± 11.0 < 0.01
# estimated hemoglobin according to ref. 
200   
Table 7. The levels of well-known predictors of ESA response in respective study period (Mean ± SD). 
 
 
Period 1 Period 2 p value
Number of dialysis sessions 76.8 ± 2.7 75.9 ± 6.4 ns
Dialyzed blood volume (L/kg/session) 0.90 ± 0.20 0.98 ± 0.18 < 0.01
s-Transferrin saturation (%) 22.2 ± 5.1 27.6 ± 9.4 < 0.05
s-Ferritin (!g/L) 470 ± 189 528 ± 243 ns
s-CRP (mg/l) 9.9 ± 7.2 12.6 ± 11.1 ns
s-Albumin (g/L) 35.8 ± 2.2 36.2 ± 3.5 ns
s-PTH (ng/L) 419 ± 384 353 ± 210 ns
Table 8. The association between changes in ERI 
and changes in predictors of ESA response 
(bivariate Spearman’s rho). 
 
rs p value
! Dialyzed blood volume (L/kg/session) -0.55 0.017
! s-Transferrin saturation (%) -0.55 0.018
! s-Ferritin ("g/L) -0.48 0.042
! s-CRP (mg/l) 0.44 0.065
! s-Albumin (g/L) 0.00 1.000
! s-PTH (ng/L) -0.19 0.453
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Table 9. The table shows the results of a multiple linear regression model with ! ERI as outcome and 
changes in factors influencing erythropoiesis as predictors.  Transferrin saturation and ferritin were omitted 
from the model because they are modified by ESA.   
! = mean changes between the periods (Period 2 - Period 1). 
 
Beta p value
Predictors lower higher
! Dialyzed blood volume (L/kg/session) -17.44 -40.71 5.84 0.130
! s-CRP (mg/l) 0.037 -0.34 0.42 0.838
! s-Albumin (g/L) 0.015 -1.13 1.16 0.979
! s-PTH (ng/L) 0.001 -0.01 0.01 0.712
95 % CI interval
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DISCUSSION 
The multifactorial etiology of renal anemia 
makes its treatment a challenge for the practicing 
nephrologist. The goal of the treatment is simple, 
a hemoglobin value between 110 and 120 g/L 10, 
68. On the other hand, keeping the hemoglobin 
level inside this tight interval is not easy. Further, 
an emphasis should be laid on “how to reach the 
target hemoglobin” rather the target itself, as this 
is probably of greatest relevance.  As illustrated 
in figure 13, the hemoglobin value in patients on 
dialysis is determined by multiple factors that 
have to be considered in the management of 
anemia in this population.  
In the studies included in this thesis, only a 
few aspects of renal anemia management have 
been touched upon; a safety issue with IV iron 
treatment, an option of attacking a fundamental 
pathogenetic factor and a possibility of reducing 
ESA dose by changing the administration praxis. 
Evaluating the potential toxicity of IV iron 
Iron is essential for all living organisms 201. Due 
to its marvelous ability to both gain and release 
electrons it can exist in various oxidative states, 
giving it a crucial role in numerous biological 
actions, such as transporting oxygen to tissues via 
hemoglobin as well as functioning as a cofactor 
in a number of enzyme systems 202. Because of 
the reactivity, iron is toxic and therefore, by 
nature, iron is never ‘free’ or unbound in 
biological systems. Accordingly, iron absorption, 
transport and storage are firmly regulated, 
preventing iron contact with substances not 
participating in iron-related biological actions or 
iron homeostasis. When iron is injected directly 
into the blood stream, the natural way of iron to 
enter the body is bypassed and large amounts of 
iron suddenly emerge in the circulation. This 
constitutes a risk for the appearance of labile and 
potentially harmful iron. Indeed, 2 - 6% of iron 
bound in the most common iron-carbohydrate 
complexes is labile and directly chelated by 
transferrin 117. If this iron isn’t properly taken 
care of by transferrin and other iron binding 
molecules, a hazardous redox reaction can occur. 
In Paper I and II this issue was investigated in 
two ways: directly, by measuring non-transferrin 
bound iron (NTBI) following IV iron injection, 
and indirectly, by measuring “footprints” of 
catalytically active iron, such as markers of 
oxidative stress.  
Non-transferrin bound iron (NTBI) 
The nature of NTBI (aka “free”, labile or 
bleomycin-detectable iron) is not entirely clear. It 
is thought to represent a small native iron “pool”, 
with nonspecific catalytic activity, bound to other 
plasma components than transferrin, such as 
albumin, citrate and phosphates 203, 204. Moreover, 
the NTBI pool appears to be related to the total 
iron content in plasma. This is illustrated in 
figure 5, which shows a significant correlation 
between total iron and NTBI in plasma from HD 
patients before hemodialysis treatment. 
Moreover, this correlation was still seen after IV 
iron injection (figure 6), which is interesting as it 
indicates that the NTBI pool increase in spite of 
available transferrin binding capacity.  
Quantifying NTBI in plasma is quite difficult, 
mainly owing to the presence of much larger 
pools of physiologically bound iron (e.g., 
transferrin, hemoglobin, and other iron-
containing proteins). In Paper I and II, an ESR 
method, based on iron chelation by 
desferrioxamine (DFO) was adapted and used for 
this purpose. By this method, ferric iron, not 
bound to transferrin, is detected. The sensitivity 
is good, making it possible to quantify low levels 
of NTBI, even in healthy individuals. This is 
Figure 13. The multifactorial predictors of hemoglobin 
production in patients on dialysis treatment. 
 
 
Hemoglobin  Iron 
ESA 
Vascular 
access 
Inflammation 
Infection Volume overload 
PTH 
Dialysis 
dose 
Nutrition 
Dialysis 
modality 
 
2%$3+4$.+"0,"5$.36"7.$483!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!"
 
>= 
shown in Paper I, where the mean level of NTBI 
in blood donors was 1.9 µM, compared to 1.6 µM 
in HD patients. Further, applying the method on 
plasma following IV iron injection (Paper I), a 
rapid increase in plasma NTBI was noted (figure 
7). This is in line with several other reports on 
appearance of NTBI after intravenous IS 
infusion, both in hemodialysis patients 117, 119, 120, 
131 and in healthy volunteers 132. 
Measurements of NTBI following IV iron 
injection can overestimate the actual level of 
NTBI in the circulation, because the assay used 
can, in fact, measure iron from the iron-
carbohydrate complex 205. This was evaluated in 
Paper I, where the ESR method was found to be 
able to measure 1.2 respective 2.2% of iron 
bound in ID and IS in vitro. Thus, there is a 
possibility that a part of the NTBI, measured 
after IV iron injections in Paper I and II, comes 
from the iron-carbohydrate complex. However, it 
seems unlikely, because transferrin, a strong iron 
chelator, should bind the majority of this iron 
during the time from injection to sample 
collection (10 minutes). Taken together, in 
studies measuring NTBI in blood following IV 
iron injection, an assay interference with the iron 
complex can never be excluded. 
Whatever the origin of NTBI, the crucial 
question is whether it is catalytically active and 
capable to induce oxidative reactions.  
Ascorbic free radical (AFR) 
AFR (semidehydroascorbate) is an intermediate 
when ascorbic acid is oxidized in one-electron 
steps into dehydroascorbate 206. It is nontoxic and 
relatively stable compared to the “primary” free 
radicals encountered in biological systems and it 
is easily detectable by ESR. Normally, low 
steady-state concentrations of AFR are found in 
plasma, conceivably reflecting generation of 
AFR from the reaction of ascorbic acid with free 
radicals. AFR can also be generated by oxidation 
of ascorbic acid in the presence of transition 
metals, such as iron, which upon reduction 
become catalytically activated as shown by 
following equation: 
  
Ascorbic acid + Fe3+  %   AFR + Fe2+ + H + 
 
Thus, in theory, if ferric iron (Fe3+) is released 
from the iron-carbohydrate complex, it is rapidly 
reduced to ferrous iron (Fe2+) by ascorbic acid, 
which in turn is oxidized to AFR. Hence, an 
increase in AFR following IV iron injection 
indicates an appearance of Fe2+, which is 
generally toxic in biological systems and can 
catalyze many reactions associated with 
oxidative tissue damage.  
In Paper I and II, it was investigated if the 
reaction described above occurs when iron is 
injected into the circulation. A huge and abrupt 
increase in AFR was found after IV injection of 
100 mg IS (figure 7) and a significant elevation 
was still seen 1 hour after the injection.  This 
supports the theory that ferrous iron has, indeed, 
appeared.   
AFR has been suggested to be an indicator of 
total oxidative burden 207 and in vitro studies 
have shown increased AFR levels in plasma 
during induced free radical stress 208 and iron 
load 209. In vivo, Galleano reported increased 
level of AFR in iron-overloaded rats 210 and the 
results reported in Paper I-II are the first on this 
topic in humans. On the other hand, this is not the 
first time ESR is used to evaluate oxidative stress 
after IV iron injection. Rooyakkers et al. used 
this technique to evaluate the generation of 
superoxide in whole blood following IV IS 
injection. A dramatic increase in superoxide was 
noted 132.  
Iron induced oxidative stress 
The fate of the iron-carbohydrate complex after 
IV injection is illustrated in figure 14. As can be 
seen, there is a possibility of oxidative reactions 
if labile iron appears in the circulation. Indeed, in 
vitro, the most commonly used IV agents; ID, IS, 
IG, have been found to release catalytically 
active iron and induce redox reactions 211. 
Further, in vivo, numerous studies have noted an 
elevation in oxidative stress markers after IV IS 
injections, as compiled in Paper II 122. On the 
other hand, not all authors have noted increased 
oxidative stress following IS injection 212-216 
making this issue a matter of controversy. In 
Paper I, after IS injection, a parallel increase in 
AFR and NTBI was observed (figure 7) and the 
strong correlation between the NTBI and AFR 
indicates a causal relationship. Previously, one 
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author has reported a significant correlation 
between NTBI and an oxidative stress marker 
following IS injection (MDA) 131.  
Comparison of iron-sucrose and low-molecular 
weight iron-dextran 
At the time of the studies in this thesis, two IV 
iron formulations were indicated for treatment of 
renal anemia in patients on chronic hemodialysis 
in Sweden; iron-sucrose (Venofer®) and low-
molecular weight iron-dextran (Cosmofer®). In 
Paper I, possible differences in stability between 
these complexes were investigated in vitro. 
During incubation with DFO over 60 minutes, a 
continuous release of iron from the IS complex 
was noted. Thus, 2.2% of the total iron bound in 
the IS complex was chelated by DFO during this 
time. Further, the dissociation was augmented by 
75% by ascorbic acid. On the other hand, the ID 
complex was significantly more stable than IS. 
During 60 minutes, DFO chelated 1.2% of the 
iron bound in the ID complex and ascorbic acid 
did not significantly increase iron dissociation 
from ID. The finding of superior stability of ID 
compared to IS is not new 117, 217. In general, 
larger iron-carbohydrate complexes are more 
stable and the MW of LMW-ID was recently 
reported as 410 kDa compared to 252 kDa for IS 
218. In the same study, free iron release from 
different IV iron agents was investigated with 
similar results as presented in Paper I. Further, in 
recent study, NTBI increased significantly more 
after IV IS than ID injection, both in HD patients 
and healthy volunteers 154.  
In Paper II, intravascular iron release and 
induction of oxidative stress after IV 
administration of IS and ID was compared. The 
NTBI “pool” enhanced significantly more after 
IS or by 86%, compared to 45% after ID. 
Interestingly, in spite of the increase in NTBI 
after ID, no increase in AFR was noted, while 
AFR rose by 29% following IS. However, ID has 
much longer half live than IS 113 so there is a 
possibility of higher cumulative intravascular 
iron release from ID over time, and an increase in 
AFR beyond 10 minutes can not be ruled out.  
The lack of AFR formation following ID 
indicates that during the time between IV iron 
injection and sample collection (10 min), iron 
released from ID was properly bound to 
transferrin and other iron-binding molecules 
(NTBI) and no fraction was catalytically active. 
On the contrary, the amount and/or speed of iron 
release from IS was overriding the entire plasma 
iron-binding capacity and a fraction of it 
appeared, at some moment, in unbound form, 
inducing undesired redox reactions. The reason 
why increased oxidative stress was not seen 
following ID is not clear, but one explanation is 
 
Fe3+ Labile iron  2-5 %  
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Figure 14. The pathways for iron after IV injection. Oxidative reactions can occur if labile iron appears. 
Ascorbic acid is an exemple of a bioreductant existing in the circulation, many others may be involved. 
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that ID and IS complexes interact differently with 
iron-binding molecules in blood and that ID in 
some way “delivers” iron directly to these 
molecules protected from the surroundings.  
Previously, it has been believed that 
transferrin “oversaturation” is necessary before 
iron can appear as “free” and catalytically active. 
For instance, this has been noted by using the 
bleomycin assay to analyze NTBI 120. This 
phenomenon was not seen in the present studies. 
Transferrin saturation were over 100 % in 10 out 
of 20 patients in Paper I and 4 out of 20 in Paper 
II, but the elevation in AFR was not only seen in 
these patients. Instead, AFR increased at any 
level of transferrin saturation, which, in theory, 
could be caused by too fast iron release from the 
IS complex. Methodological aspects could 
explain the discrepancy between the results 
presented here and those from studies conducted 
with the bleomycin assay, as the sensitivity of the 
ESR method is much higher. For example, the 
bleomycin assay is not able to measure NTBI 
levels in patients before IV iron injection 120.   
Iron overload 
The issue of harmful iron overload in HD 
patients has been evaluated in several studies. 
Two studies have reported a significant 
correlation between the level of atherosclerosis 
and annual IV iron dose 155, 219, Feldman et al. 
described increased hospitalization and mortality 
with IV iron doses exceeding 1000 mg over 6 
months 156, Brookhart et al. reported elevated 
mortality risk with greater iron use 158 and 
increased mortality has been associated with 
ferritin levels above 800 µg/L 157 as well as levels 
above 600 µg/L independently of the C-reactive 
protein level 220. In addition, in two large cohort 
studies, IV iron doses above 400 - 450 mg per 
month were significantly correlated with higher 
death rates 157, 221. The patients participating in 
this thesis had an average ferritin level of 350 
µg/L (assemblage of all four observation periods) 
and it can be concluded that these patients were 
not suffering from severe iron overload.  
The diagnosis of iron overload is not easily 
performed in clinical praxis because ferritin, the 
marker of total iron stores, is difficult to interpret 
because of its behavior as an acute phase 
reactant, increasing secondarily to non-iron 
related factors such as inflammation and 
malnutrition. As these conditions are frequently 
found in CKD patients, 222, ferritin levels above 
normal have been considered safe in this patient 
population. In recent study, using non-invasive 
MRI technology, serum ferritin was useless in 
predicting liver iron content 223. Instead, liver 
iron was strongly correlated to cumulated iron 
dose and time on dialysis. This is in contrast to 
an earlier, non-invasive study that measured liver 
iron concentration in HD patients with a 
noninvasive magnetic method, called SQUID 
(superconducting quantum interference device). 
In this study Canavese et al. reported a good 
correlation between hepatic iron content and 
ferritin levels in HD patients without ongoing 
inflammation 224. Interestingly, both studies 
found iron overload even at ferritin levels that are 
generally considered safe. On the other hand, no 
data exists on a possible relationship between 
high iron load in ESRD and tissue damage 225. 
High iron load not only leads to high serum 
ferritin levels, but also to high levels of serum 
hepcidin 34, 37. Indeed, a significant correlation 
between those two parameters has been described 
37, 39, 226, 227 and the results in Paper III are in line 
with this finding. High levels of hepcidin lead to 
decreased iron absorption and locking of iron in 
stores. This is a normal physiological response to 
iron overload and even during infections, as iron 
is important for the virulence of the 
microorganisms and can impair neutrophil 
function 120, 160, 161. On the opposite, the hepcidin 
levels decrease when iron levels are low or when 
more iron is required for erythropoiesis, as 
happens with ESA treatment 227, 228.  
In theory, there is a possibility that repeated 
IV iron injections create a vicious circle (figure 
15). When high amounts of iron are injected into 
the circulation, the body interprets this as acute 
iron load and, in defense, promptly increases the 
level of hepcidin 37, 40, 229. Keeping in mind that 
high hepcidin levels and functional iron 
deficiency are common in uremia, replicated IV 
iron loadings could, in spite of temporary 
elevation in transferrin saturation, could 
aggravate this condition by maintaining high 
hepcidin levels and low transferrin saturation 
over time. Low transferrin saturation indicates 
treatment with more IV iron and the process can 
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continue, finally resulting in iron overload. 
Judging from this hypothesis, treatment of 
functional iron deficiency with additional iron 
injections, as has been advocated by the DRIVE 
study 230, should be executed with caution. 
Taken together, the risk for iron overload with 
long term IV iron treatment cannot be neglected. 
In US, the mean IV iron dose administrated to 
HD patients has been gradually increasing, and 
was, in 2006, 4.2 g/year 231, which is in great 
excess of the predicted iron loss of 1-2 g/year 31. 
As a result, the serum ferritin levels have 
gradually increased, and in 2007 the mean levels 
in the HD population in US and Sweden were 
approximately 550 µg/L 232. Moreover, 30% of 
the US patients had serum ferritin above 800 
µg/L 233, which are levels that have been 
associated with increased mortality risk 157. In 
spite of the controversial significance of ferritin 
in judging iron status, this trend is of concern and 
a recent observation supports that HD patients 
are given iron in excess of what is needed 234. In 
this report, 26 iron-replete HD patients (mean 
ferritin = 503 µg/L) were able to maintain stable 
hemoglobin and ESA dose despite that all iron 
treatment was withheld for 16 weeks.  
Attacking hepcidin 
In Paper III, a broad comparison of two dialysis 
modalities, low-flux hemodialysis (HD) and 
hemodiafiltration (HDF), was performed. The 
overall results of this study were negative. In 
other words, no differences in clinically relevant 
parameters were seen. On the other hand, serum 
hepcidin levels were within the normal reference 
interval in all cases after treatment with HDF and 
38 % lower than after treatment with HD. Even 
though the corresponding pre-dialysis levels were 
not measured, this indicates that HDF eliminates 
hepcidin more effectively than HD.  
Studies on elimination of hepcidin by dialysis 
are sparse. Surprisingly, Ashby et al. did not 
observe any significant elimination of hepcidin 
with low flux HD 37, 235 while Weiss et al. found 
a significant elimination of hepcidin by both low 
flux HD and HDF 227. Further, in a recent study, 
using a new high-flux dialyzer (Gambro 
Revaclear®), which effectively removes middle 
molecular weight substances, a 50% reduction in 
serum hepcidin levels was found 236.  
The clinical benefit of lowering hepcidin 
levels by HDF remains to be investigated. 
However, as described earlier, patients on 
dialysis often suffer from functional iron 
deficiency, mainly caused by pathologically high 
levels of circulating hepcidin 237. Therefore, it 
seems reasonable that efforts in lowering the 
level of hepcidin will bring the iron homeostasis 
towards a more normal state. The finding in 
Paper III, of a trend towards lower ferritin levels 
and increased MCV after 2 months treatment 
with HDF, is in line with this hypothesis, 
indicating iron mobilization from the stores. This 
is further supported by another study reporting 
lower ferritin levels and improved iron utilization 
with HDF 185. Taken together, it is rational to 
include treatment strategies attempting to lower 
hepcidin level in CKD patients. This can be 
achieved by lowering total iron load, increasing 
elimination by dialysis, or, hopefully in the 
future, specifically decrease the hepcidin levels 
by some kind of hepcidin-antagonists 237. 
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Figure 15. A theory of a vicious circle, created by 
repeated IV iron injections. 
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The schedule of ESA administration  
In Paper IV, an explanation to the observed 
22.5% drop in ESA utilization was sought. This 
decrease was noted after a change in the ESA 
administration practice and the hypothesis was 
that the new routine, with fewer dose adjustment 
and no withheld doses, could save ESA. Such an 
assumption can only be made by ruling out other 
possible explanations, such as changes in factors 
that are known to affect erythropoiesis. We 
systematically evaluated these factors and found 
two other theoretical explanations; increased 
dialysis dose and higher transferrin saturation.  
An inverse correlation has been described 
between the adequacy of dialysis and changes in 
ERI 76. This was observed in Paper IV, where 
change in dialysis dose was negatively correlated 
to changes in ERI, albeit, in a multiple regression 
model, dialysis dose was not a significant 
independent predictor of ERI. However, there is 
a possibility of type-2 error here, as CI for beta 
was wide and predominantly negative. In such 
case, increased dialysis dose could explain a 
decrease in ESA need. If true, this is in contrast 
to previous studies in patients on hemodialysis 
thrice weekly, reporting that the beneficial effect 
of dialysis dose on erythropoiesis vanishes at 
Kt/V > 1.3 69, 183.  
Surprisingly, s-transferrin saturation was 
significantly higher after the change in ESA 
administration praxis. This was not explained by 
increased iron dose and if true, this could explain 
lower ERI because changes in transferrin 
saturation were found to predict changes in 
hemoglobin. However, most likely, higher 
transferrin saturation was due to a shorter interval 
between IV iron injection and measurement of 
iron parameters in the study period with the new 
ESA administration routine. Another possible 
explanation is that more patients were treated 
with iron-dextran in this period, while iron-
sucrose was predominantly used before the 
change. Iron-dextran has longer half-life 113 and it 
is possible that a more long-lasting elevation of 
transferrin saturation occur after injection with 
iron-dextran than iron-sucrose. Further, 
withholding ESA doses, which was frequently 
practiced before the routine change, can affect 
iron homeostasis in various ways through factors  
like neocytolysis (see below), iron utilization and 
hepcidin.  
The major limitation of Paper IV is that the 
study is small and observational. Optimally, the 
results should be confirmed by prospective 
randomized trials that can give answers to the 
following questions raised by our work: Does 
neocytolysis occur when ESA dose are withheld? 
Is there any difference between iron-sucrose and 
iron-dextran regarding transferrin saturation over 
time and response to ESA? Can we reduce ESA 
need in patients already receiving adequate 
dialysis dose (Kt/V > 1.3) three times a week by 
increasing the dialysis dose? 
Taken together, the reason for the lower ESA 
requirement after the change in ESA 
administration practice is not clear. However, it 
is fair to conclude that ESA administration 
praxis, where ESA doses are withheld, does not 
reduce ESA demand. Instead, such practice could 
be associated with higher ESA requirement over 
time and, indeed, there is a possibility of 
neocytolysis when ESA doses are withheld.  
The theory of neocytolysis  
Neocytolysis is a normal physiological reaction 
that occurs when the body needs to adapt rapidly 
to an inappropriately high red-cell mass. In this 
process, young erythrocytes (neocytes) are 
selectively removed from the circulation by 
hemolysis in the spleen. The mechanism is not 
entirely elucidated, but the process is thought to 
start by a sudden drop in erythropoietin 
production 238. Macrophages in the spleen 
recognize neocytes by adhesion molecules on 
their cell surface and it is believed that 
erythropoietin, in some way, disturbs the 
interaction between the neocytes, spleen 
endothelial cells and the macrophages, impeding 
the phagocytosis 239. It is not clear if it is a nadir 
or if it is the sudden drop in erythropoietin 
concentration that initiates the process 240, but it 
has been postulated that neocytolysis can 
contribute to anemia in HD patients when EPO 
doses are withheld 241. Moreover, erythropoietin 
prevents apoptotic death of erythroid precursor 
cells 61-63 so another potential consequence of 
withholding ESA dose is more pronounced loss 
of these cells, resulting in fewer mature 
erythrocytes.  
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Treating renal anemia in the future  
Heme iron. 
Heme iron, a natural nutrition supplement with 
excellent absorption and no side effects, should, 
in theory, be the iron-treatment of choice in renal 
anemia. Indeed, one study in patients on chronic 
hemodialysis supports this 110. Another study, on 
peritoneal dialysis patients 242 is on the horizon, 
but more data are urgently needed before such 
oral treatment with concentrated heme iron can 
be generally recommended in renal anemia.  
Contemporary IV iron agents 
In recent years new IV iron formulations with 
better safety profiles have been developed 114. 
Currently, three are on the market; iron-
carboxymaltose (Ferinject®), and iron 
isomaltoside 1000 (Monofer®) in Europe and 
ferumoxytol (Feraheme®) in the US. All these 
agents are very stable with low risk of 
spontaneous iron release, which means that they 
can be given in very high doses. Further, all have 
very low immunogenic activity indicating 
minimal risk of anaphylactic reactions. Taken 
together, the safety profile of these new agents is 
promising, but more studies are needed before we 
can state that induction of oxidative stress and the 
frequency of hypersensitivity reactions is lower 
compared to older IV iron agents.  
Prolyl hydroxylase inhibitors  
During the last decade, several prolyl 
hydroxylase inhibitors (PHI) have been 
developed. By inhibiting this enzyme, the 
degradation of hypoxia inducible factor (HIF) is 
suppressed, resulting in enhanced HIF 
bioavailability. The consequences of increasing 
HIF are twofold; EPO production is stimulated 
243 and hepcidin production is down-regulated 20. 
This sounds ideal, as opposite changes in EPO 
and hepcidin production are fundamental 
etiological factors in renal anemia.  
Few studies have been conducted so far, 
evaluating the effect of PHI on erythropoiesis. 
An oral PHI (FG-2216) has been found to 
stimulate EPO production and increase the 
hemoglobin level in healthy and anemic monkeys 
243 and recently, in a study on HD patients using 
the same substance, a several-fold increase in 
serum EPO levels were noted 26. Interestingly, a 
15-fold increase in serum EPO was found in 
anephric HD patients, arguing for an extrarenal 
production. These findings are exciting, but we 
have to bear in mind that more than 70 HIF target 
genes have been identified, which may limit the 
specificity of this approach 244. Without doubt, 
we are going to learn more about PHI in the 
future and, if well tolerated and safe, these agents 
could become an alternative to ESA and IV iron 
in the treatment of renal anemia. 
Erythropoietin-mimetic peptide 
In recent years, erythropoiesis-stimulating 
peptide (Hematide) has been developed. It has a 
unique amino acid sequence, totally different 
from native erythropoietin or available ESAs, 245. 
Despite that, it binds to the EPO receptor and 
stimulates EPO production in a dose-dependent 
way. Hematide has been safely administrated to 
healthy volunteers and to CKD patients, and 
following a single IV injection a boost in 
hemoglobin, lasting for more than 1 month, was 
seen 246, 247. Because of the dissimilarity to 
erythropoietin, anti-EPO antibody production, 
leading to pure red cell anemia, is not seen. 
Instead, this dreaded condition can be 
successfully treated with Hematide 248, which in 
such case is the only treatment available. 
Ferric pyrophosphate 
A new approach for iron supplementation in 
patients on chronic hemodialysis is currently 
under investigation. Soluble ferric pyrophosphate 
(SFP) is a low MW iron salt (~1000 Da) that can 
be delivered to the patient’s circulation via the 
dialysate. By this approach, iron diffuses slowly 
from the dialysate to the circulation during the 
hemodialysis treatment 249. It is then rapidly 
taken up by circulating transferrin 250 and phase 
II trials, have reported adequate erythropoiesis 
251. Unlike other IV iron agents, SFP has no 
carbohydrate shell, which minimizes the risk of 
allergic reactions. Moreover, the complex is very 
stable with low risk for appearance of labile iron. 
In addition, pyrophosphate is a potent antioxidant 
252 and inhibitor of vascular calcifications 253, 254, 
properties that could be of benefit in patients with 
ESRD. Thus, SEP can be an interesting option 
for iron treatment in HD patients in the future. 
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CONCLUSIONS 
• ESR is a robust, reliable and sensitive 
technique for measuring NTBI and AFR 
in plasma.  
• A NTBI “pool” is found in both healthy 
and HD patients and its size is 
proportional to the total iron content in 
plasma. 
• A burst of oxidative stress occurs in the 
circulation after IV injection of iron-
sucrose. The magnitude of the oxidative 
reaction is closely correlated to the 
amount of iron released from the IS 
complex. A risk of oxidative injury to 
hemodialysis patients repeatedly 
receiving this type of intravenous iron 
supplementation cannot be disregarded. 
• Due to the simplicity and reliability, 
measuring AFR should be the method of 
choice in monitoring the appearance of 
catalytically active iron following 
intravenous iron injection. 
• Following IV injection of low-molecular 
weight iron-dextran, iron release is 
significantly lower than after iron-sucrose 
and no direct induction of oxidative stress 
is seen. 
• The level of serum hepcidin is 
significantly lower after treatment with 
hemodiafiltration than low-flux 
hemodialysis. Keeping in mind that an 
increase in circulating hepcidin is a 
fundamental abnormality in renal anemia, 
efforts in lowering this level could bring 
the iron homeostasis towards a more 
normal state.  
• Frequent dose adjustments and an ESA 
administration praxis where ESA doses 
are withheld do not reduce ESA demand. 
Instead, such practice could be associated 
with higher ESA requirement over time. 
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